Hemolytic-uremic syndrome epidemiology and demographics: Difference between revisions
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
The highest proportion of HUS cases (15.3%) occurred among children aged <5 years. HUS affects female more than male and white race more than other races. Mortality is more commonly seen in elderly patients in which disease is less common but more dangerous. | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
Line 27: | Line 28: | ||
*The incidence of HUS increases with age; the median age at diagnosis is younger than 5 years.<ref name="KarpmanLoos2017">{{cite journal|last1=Karpman|first1=Diana|last2=Loos|first2=Sebastian|last3=Tati|first3=Ramesh|last4=Arvidsson|first4=Ida|title=Haemolytic uraemic syndrome|journal=Journal of Internal Medicine|volume=281|issue=2|year=2017|pages=123–148|issn=09546820|doi=10.1111/joim.12546}}</ref> | *The incidence of HUS increases with age; the median age at diagnosis is younger than 5 years.<ref name="KarpmanLoos2017">{{cite journal|last1=Karpman|first1=Diana|last2=Loos|first2=Sebastian|last3=Tati|first3=Ramesh|last4=Arvidsson|first4=Ida|title=Haemolytic uraemic syndrome|journal=Journal of Internal Medicine|volume=281|issue=2|year=2017|pages=123–148|issn=09546820|doi=10.1111/joim.12546}}</ref> | ||
*HUS commonly affects individuals younger 5 | *HUS commonly affects individuals younger than 5 years of age.<ref name="KarpmanLoos2017">{{cite journal|last1=Karpman|first1=Diana|last2=Loos|first2=Sebastian|last3=Tati|first3=Ramesh|last4=Arvidsson|first4=Ida|title=Haemolytic uraemic syndrome|journal=Journal of Internal Medicine|volume=281|issue=2|year=2017|pages=123–148|issn=09546820|doi=10.1111/joim.12546}}</ref> | ||
===Race=== | ===Race=== | ||
*HUS usually affects individuals of the White race (82%).<ref name=":0" /> | *HUS usually affects individuals of the White race (82%).<ref name=":0" /> |
Revision as of 19:11, 8 August 2018
Hemolytic-uremic syndrome Microchapters |
Differentiating Hemolytic-uremic syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hemolytic-uremic syndrome epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Hemolytic-uremic syndrome epidemiology and demographics |
FDA on Hemolytic-uremic syndrome epidemiology and demographics |
CDC on Hemolytic-uremic syndrome epidemiology and demographics |
Hemolytic-uremic syndrome epidemiology and demographics in the news |
Blogs on Hemolytic-uremic syndrome epidemiology and demographics |
Risk calculators and risk factors for Hemolytic-uremic syndrome epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
The highest proportion of HUS cases (15.3%) occurred among children aged <5 years. HUS affects female more than male and white race more than other races. Mortality is more commonly seen in elderly patients in which disease is less common but more dangerous.
Epidemiology and Demographics
Incidence
- In children less than 5 years of age, the incidence of HUS is approximately 8.5 per 100,000.[1]
Mortality rate
- In 2017, the mortality of hemolytic uremic syndrome (HUS) is estimated to approximately 10% .[2]
Age
- Patients of all age groups may develop hemolytic uremic syndrome (HUS).
- The incidence of HUS increases with age; the median age at diagnosis is younger than 5 years.[3]
- HUS commonly affects individuals younger than 5 years of age.[3]
Race
- HUS usually affects individuals of the White race (82%).[4]
Gender
- HUS affects female more than male. Approximately 59% of affected individuals are female.[4]
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
References
- ↑ Mele, Caterina; Remuzzi, Giuseppe; Noris, Marina (2014). "Hemolytic uremic syndrome". Seminars in Immunopathology. 36 (4): 399–420. doi:10.1007/s00281-014-0416-x. ISSN 1863-2297.
- ↑ Gregory Hall, Shinichiro Kurosawa & Deborah J. Stearns-Kurosawa (2017). "Shiga Toxin Therapeutics: Beyond Neutralization". Toxins. 9 (9). doi:10.3390/toxins9090291. PMID 28925976. Unknown parameter
|month=
ignored (help) - ↑ 3.0 3.1 Karpman, Diana; Loos, Sebastian; Tati, Ramesh; Arvidsson, Ida (2017). "Haemolytic uraemic syndrome". Journal of Internal Medicine. 281 (2): 123–148. doi:10.1111/joim.12546. ISSN 0954-6820.
- ↑ 4.0 4.1 Deirdra R. Terrell, Sara K. Vesely, Johanna A. Kremer Hovinga, Bernhard Lammle & James N. George (2010). "Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes". American journal of hematology. 85 (11): 844–847. doi:10.1002/ajh.21833. PMID 20799358. Unknown parameter
|month=
ignored (help)